Studies targeting CPT1A have shown that, compared to the primary site, the expression level of CPT1A in metastatic sites is significantly increased, and inhibiting CPT1A expression can reduce the lung metastatic rate of CRC. This evidence concerns the gene CPT1A and colorectal carcinoma.